Search Results

You are looking at 1 - 10 of 320 items for :

  • Refine by Access: All x
Clear All
Full access

Guideline Familiarity Predicts Variation in Self-Reported Use of Routine Surveillance PET/CT by Physicians Who Treat Head and Neck Cancer

Benjamin R. Roman, Snehal G. Patel, Marilene B. Wang, Anna M. Pou, F. Christopher Holsinger, David Myssiorek, David Goldenberg, Samuel Swisher-McClure, Alexander Lin, Jatin P. Shah, and Judy A. Shea

Cancers, which recommend only “further reimaging as indicated based on signs/symptoms.” 1 Routine surveillance imaging for asymptomatic patients in other cancer types has been identified as a target for reduction. 2 – 5 Recently, PET/CT for surveillance

Full access

PET/CT and Occult Primary Tumors

Donald A. Podoloff

-modality PET/CT—initial experience . Radiology 2005 ; 234 : 227 – 234 . 7 Kolesnikov-Gauthier H Levy E Merlet P . FDG PET in patients with cancer of an unknown primary . Nucl Med Commun 2005 ; 26 : 1059 – 1066 . 8 Mevio E Gorini E

Full access

CT-Based Versus FDG-PET/CT–Based NCCN International Prognostic Index Risk Stratification in DLBCL

Hugo J.A. Adams, John M.H. de Klerk, Rob Fijnheer, Stefan V. Dubois, Rutger A.J. Nievelstein, and Thomas C. Kwee

, Ann Arbor stage, and ECOG performance status. Unfortunately, the NCCN-IPI does not specify which imaging modality should be used to detect extranodal disease in major organs and determine Ann Arbor stage. 4 CT and 18 F-fluoro-2-deoxy-D-glucose PET/CT

Full access

Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II–III Breast Cancer: A Multicenter Value Analysis

Colby J. Hyland, Flora Varghese, Christina Yau, Heather Beckwith, Katia Khoury, William Varnado, Gillian L. Hirst, Robert R. Flavell, A. Jo Chien, Douglas Yee, Claudine J. Isaacs, Andres Forero-Torres, Laura J. Esserman, and Michelle E. Melisko

population for clinical trials in adjuvant and neoadjuvant settings. 5 18 F-FDG PET/CT (PET/CT) is effective in detecting regional and distant metastases 4 – 8 and has outperformed standard imaging techniques in the detection of bone, lymph node, and liver

Full access

Clinical Utility of 18F-FDG PET/CT in Staging Localized Breast Cancer Before Initiating Preoperative Systemic Therapy

Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano

category 2B evidence. 3 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/CT is considered optional in circumstances in which CTBS is equivocal or suspicious. Prior studies reported greater sensitivity of PET/CT versus CT of the body for the detection of regional

Full access

NCCN Task Force Report: Positron Emission Tomography (PET)/Computed Tomography (CT) Scanning in Cancer

Donald A. Podoloff, Ranjana H. Advani, Craig Allred, Al B. Benson III, Elizabeth Brown, Harold J. Burstein, Robert W. Carlson, R. Edward Coleman, Myron S. Czuczman, Dominique Delbeke, Stephen B. Edge, David S. Ettinger, Frederic W. Grannis Jr., Bruce E. Hillner, John M. Hoffman, Krystyna Kiel, Ritsuko Komaki, Steven M. Larson, David A. Mankoff, Kenneth E. Rosenzweig, John M. Skibber, Joachim Yahalom, JQ Michael Yu, and Andrew D. Zelenetz

characterization and measurement of biologic processes at the cellular and molecular level.” PET is considered the prototypical molecular imaging technique, with PET/CT providing combined anatomic and molecular imaging. PET imaging is based on a unique chemical

Full access

QIM19-133: Assessing and Reducing FDG PET/CT Radiotracer Infiltrations: Lessons in Quality Improvement Sustainability

Jackson W. Kiser, James Crowley, Thad Benefield, Ronald Lattanze, Steve Perrin, Kelley Ryan, and Josh Knowland

Background: Oncologic PET/CT studies require a prescribed 18 F-fluorodeoxyglucose (FDG) dose delivered as a bolus prior to imaging; this same dose is used in the standardized uptake value (SUV) calculation. An infiltration is the misadministration

Full access

CLO20-034: First U.S. Prospective Evaluation of Performance of 64Cu DOTATATE PET/CT in Somatostatin Expressing Neuroendocrine Tumors

E. S. Delpassand, Rodolfo Nunez, D. Ranganathan, N. Wagh, A. Shafie, A. Gaber, I. Tworowska, and A. Abbasi

the country. Objective: The study aim was to prospectively evaluate the safety and diagnostic performance of 64 Cu-DOTATATE PET/CT in detection of SST expressing NET. Method: All subjects received 4.0 ± 10% mCi of 64 Cu-DOTATATE and PET/CT imaging

Full access

Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?

David Groheux, Elif Hindié, Marc Espié, and Gary A. Ulaner

Re: Hyland CJ, Varghese F, Yau F, et al. Use of 18F-FDG PET/CT as an initial staging procedure for stage II–III breast cancer: a multicenter value analysis. J Natl Compr Canc Netw 2020;18(11):1510–1517. We read with interest the article by

Full access

Evaluating the Potential Role of PET/CT in the Posttreatment Surveillance of Head and Neck Cancer

Shrujal S. Baxi, Lara Dunn, and David G. Pfister

cancer. PET/CT after treatment is only specifically mentioned in the context of a decision algorithm for assessing whether to perform a neck dissection or observe the neck after chemoradiation or radiation treatment. 1 Otherwise, the NCCN Guidelines for